Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2013, Article ID 396839, 11 pages
http://dx.doi.org/10.1155/2013/396839
Review Article

Novel Strategies for the Treatment of Chondrosarcomas: Targeting Integrins

1Graduate Institute of Basic Medical Science, China Medical University, No. 91, Hsueh-Shih Road, Taichung 40402, Taiwan
2National Institute of Cancer Research, National Health Research Institutes, Miaoli 35053, Taiwan
3School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung 40402, Taiwan
4Department of Orthopedic Surgery, China Medical University Hospital, Taichung 40402, Taiwan
5Department of Pharmacology, School of Medicine, China Medical University, Taichung 40402, Taiwan
6Department of Biotechnology, College of Health Science, Asia University, Taichung 41354, Taiwan

Received 29 October 2013; Accepted 9 December 2013

Academic Editor: Po-Lin Kuo

Copyright © 2013 Jui-Chieh Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. E. Larsson and R. Lorentzon, “The geographic variation of the incidence of malignant primary bone tumors in Sweden,” Journal of Bone and Joint Surgery A, vol. 56, no. 3, pp. 592–600, 1974. View at Google Scholar · View at Scopus
  2. J. Bjornsson, R. A. McLeod, K. K. Unni, D. M. Ilstrup, and D. J. Pritchard, “Primary chondrosarcoma of long bones and limb girdles,” Cancer, vol. 83, no. 10, pp. 2105–2119, 1998. View at Google Scholar
  3. A. Angelini, G. Guerra, A. F. Mavrogenis, E. Pala, P. Picci, and P. Ruggieri, “Clinical outcome of central conventional chondrosarcoma,” Journal of Surgical Oncology, vol. 106, no. 8, pp. 929–937, 2012. View at Publisher · View at Google Scholar
  4. F. Bertoni, P. Bacchini, and P. C. W. Hogendoorn, “Pathology and genetics. Tumours of soft tissue and bone: chondrosarcoma,” in World Health Organization Classification of Tumors, pp. 247–251, IARC Press, Lyon, France, 2002. View at Google Scholar
  5. H. Gelderblom, P. C. W. Hogendoorn, S. D. Dijkstra et al., “The clinical approach towards chondrosarcoma,” Oncologist, vol. 13, no. 3, pp. 320–329, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. H. L. Evans, A. G. Ayala, and M. M. Romsdahl, “Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading,” Cancer, vol. 40, no. 2, pp. 818–831, 1977. View at Google Scholar · View at Scopus
  7. C. Y. Inwards and K. K. Unni, “Classification and grading of bone sarcomas,” Hematology/Oncology Clinics of North America, vol. 9, no. 3, pp. 545–569, 1995. View at Google Scholar · View at Scopus
  8. G. Ayala, C. Liu, R. Nicosia, S. Horowitz, and R. Lackman, “Microvasculature and VEGF expression in cartilaginous tumors,” Human Pathology, vol. 31, no. 3, pp. 341–346, 2000. View at Google Scholar · View at Scopus
  9. H. Welkerling, S. Kratz, V. Ewerbeck, and G. Delling, “A reproducible and simple grading system for classical chondrosarcomas. Analysis of 35 chondrosarcomas and 16 enchondromas with emphasis on recurrence rate and radiological and clinical data,” Virchows Archiv, vol. 443, no. 6, pp. 725–733, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. H. D. Dorfman and B. Czerniak, “Malignant cartilage tumors,” in Bone Tumors, pp. 353–440, Mosby, Saint Louis, Mo, USA, 1998. View at Google Scholar
  11. C.-H. Tang, “Molecular mechanisms of chondrosarcoma metastasis,” BioMedicine, vol. 2, no. 3, pp. 92–98, 2012. View at Google Scholar
  12. D. Donati, A. El Ghoneimy, F. Bertoni, C. Di Bella, and M. Mercuri, “Surgical treatment and outcome of conventional pelvic chondrosarcoma,” Journal of Bone and Joint Surgery B, vol. 87, no. 11, pp. 1527–1530, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Etchebehere, O. P. de Camargo, A. T. Croci, C. R. C. M. Oliveira, and A. M. Baptista, “Relationship between surgical procedure and outcome for patients with grade I chondrosarcomas,” Clinics, vol. 60, no. 2, pp. 121–126, 2005. View at Google Scholar · View at Scopus
  14. A. R. Harwood, J. I. Krajbich, and V. L. Fornasier, “Radiotherapy of chondrosarcoma of bone,” Cancer, vol. 45, no. 11, pp. 2769–2777, 1980. View at Google Scholar · View at Scopus
  15. R. Krochak, A. R. Harwood, B. J. Cummings, and I. C. Quirt, “Results of radical radiation for chondrosarcoma of bone,” Radiotherapy and Oncology, vol. 1, no. 2, pp. 109–115, 1983. View at Google Scholar · View at Scopus
  16. F. Y. Lee, H. J. Mankin, G. Fondren et al., “Chondrosarcoma of bone: an assessment of outcome,” Journal of Bone and Joint Surgery A, vol. 81, no. 3, pp. 326–338, 1999. View at Google Scholar · View at Scopus
  17. J. V. M. G. Bovée, A.-M. Cleton-Jansen, A. H. M. Taminiau, and P. C. W. Hogendoorn, “Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment,” The Lancet Oncology, vol. 6, no. 8, pp. 599–607, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. R. M. Terek, G. K. Schwartz, K. Devaney et al., “Chemotherapy and P-glycoprotein expression in chondrosarcoma,” Journal of Orthopaedic Research, vol. 16, no. 5, pp. 585–590, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. J. J. Wyman, A. M. Hornstein, P. A. Meitner et al., “Multidrug resistance-1 and p-glycoprotein in human chondrosarcoma cell lines: expression correlates with decreased intracellular doxorubicin and in vitro chemoresistance,” Journal of Orthopaedic Research, vol. 17, no. 6, pp. 935–940, 1999. View at Publisher · View at Google Scholar
  20. R. Rathinam and S. K. Alahari, “Important role of integrins in the cancer biology,” Cancer and Metastasis Reviews, vol. 29, no. 1, pp. 223–237, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. R. O. Hynes, “Integrins: bidirectional, allosteric signaling machines,” Cell, vol. 110, no. 6, pp. 673–687, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Barczyk, S. Carracedo, and D. Gullberg, “Integrins,” Cell and Tissue Research, vol. 339, no. 1, pp. 269–280, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. S. L. Goodman and M. Picard, “Integrins as therapeutic targets,” Trends in Pharmacological Sciences, vol. 33, no. 7, pp. 405–412, 2012. View at Publisher · View at Google Scholar
  24. O. Vinogradova, A. Velyvis, A. Velyviene et al., “A structural mechanism of integrin αIIbβ3 “inside-out” activation as regulated by its cytoplasmic face,” Cell, vol. 110, no. 5, pp. 587–597, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. K. R. Legate and R. Fässler, “Mechanisms that regulate adaptor binding to β-integrin cytoplasmic tails,” Journal of Cell Science, vol. 122, no. 2, pp. 187–198, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. J. A. Askari, P. A. Buckley, A. P. Mould, and M. J. Humphries, “Linking integrin conformation to function,” Journal of Cell Science, vol. 122, no. 2, pp. 165–170, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. A. W. Partridge, S. Liu, S. Kim, J. U. Bowie, and M. H. Ginsberg, “Transmembrane domain helix packing stabilizes integrin αIIbβ3 in the low affinity state,” The Journal of Biological Chemistry, vol. 280, no. 8, pp. 7294–7300, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Moser, K. R. Legate, R. Zent, and R. Fässler, “The tail of integrins, talin, and kindlins,” Science, vol. 324, no. 5929, pp. 895–899, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. S. J. Shattil, C. Kim, and M. H. Ginsberg, “The final steps of integrin activation: the end game,” Nature Reviews Molecular Cell Biology, vol. 11, no. 4, pp. 288–300, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. W. Guo, Y. Pylayeva, A. Pepe et al., “β4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis,” Cell, vol. 126, no. 3, pp. 489–502, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. I. Macias-Perez, C. Borza, X. Chen et al., “Loss of integrin α1β1 ameliorates kras-induced lung cancer,” Cancer Research, vol. 68, no. 15, pp. 6127–6135, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Huveneers, I. van den Bout, P. Sonneveld, A. Sancho, A. Sonnenberg, and E. H. J. Danen, “Integrin αvβ3 controls activity and oncogenic potential of primed c-Src,” Cancer Research, vol. 67, no. 6, pp. 2693–2700, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. J. S. Desgrosellier, L. A. Barnes, D. J. Shields et al., “An integrin α v Β 3-c-Src oncogenic unit promotes anchorage-independence and tumor progression,” Nature Medicine, vol. 15, no. 10, pp. 1163–1169, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. L. Huck, S. M. Pontier, D. M. Zuo, and W. J. Muller, “β1-integrin is dispensable for the induction of ErbB2 mammary tumors but plays a critical role in the metastatic phase of tumor progression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 35, pp. 15559–15564, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Miyamoto, H. Teramoto, J. S. Gutkind, and K. M. Yamada, “Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of integrin aggregation and occupancy of receptors,” Journal of Cell Biology, vol. 135, no. 6, pp. 1633–1642, 1996. View at Publisher · View at Google Scholar · View at Scopus
  36. L. Moro, M. Venturino, C. Bozzo et al., “Integrins induce activation of EGF receptor: role in MAP kinase induction and adhesion-dependent cell survival,” EMBO Journal, vol. 17, no. 22, pp. 6622–6632, 1998. View at Google Scholar · View at Scopus
  37. Y. Ning, R. Zeineldin, Y. Liu, M. Rosenberg, M. S. Stack, and L. G. Hudson, “Down-regulation of integrin α2 surface expression by mutant epidermal growth factor receptor (EGFRvIII) induces aberrant cell spreading and focal adhesion formation,” Cancer Research, vol. 65, no. 20, pp. 9280–9286, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. S. De, O. Razorenova, N. P. McCabe, T. O'Toole, J. Qin, and T. V. Byzova, “VEGF—integrin interplay controls tumor growth and vascularization,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 21, pp. 7589–7594, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. G. H. Mahabeleshwar, W. Feng, K. Reddy, E. F. Plow, and T. V. Byzova, “Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis,” Circulation Research, vol. 101, no. 6, pp. 570–580, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Engl, B. Relja, D. Marian et al., “CXCR4 chemokine receptor mediates prostate tumor cell adhesion through α5 and β3 integrins,” Neoplasia, vol. 8, no. 4, pp. 290–301, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. T. N. Hartmann, J. A. Burger, A. Glodek, N. Fujii, and M. Burger, “CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells,” Oncogene, vol. 24, no. 27, pp. 4462–4471, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. J. J. Grzesiak, K. C. Smith, D. W. Burton, L. J. Deftos, and M. Bouvet, “Integrin-mediated laminin-1 adhesion upregulates CXCR4 and IL-8 expression in pancreatic cancer cells,” Surgery, vol. 141, no. 6, pp. 804–814, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. K. M. Yamada and S. Even-Ram, “Integrin regulation of growth factor receptors,” Nature Cell Biology, vol. 4, no. 4, pp. E75–E76, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. G. Giannelli, E. Fransvea, F. Marinosci et al., “Transforming growth factor-β1 triggers hepatocellular carcinoma invasiveness via α3β1 integrin,” American Journal of Pathology, vol. 161, no. 1, pp. 183–193, 2002. View at Google Scholar · View at Scopus
  45. C.-M. Wu, T.-M. Li, S.-F. Hsu et al., “IGF-I enhances α5β1 integrin expression and cell motility in human chondrosarcoma cells,” Journal of Cellular Physiology, vol. 226, no. 12, pp. 3270–3277, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. C. Y. Lin, H. J. Chen, T. M. Li et al., “beta5 integrin up-regulation in brain-derived neurotrophic factor promotes cell motility in human chondrosarcoma,” PLoS ONE, vol. 8, no. 7, Article ID e67990, 2013. View at Google Scholar
  47. C.-Y. Lee, C.-Y. Huang, M.-Y. Chen, C.-Y. Lin, H.-C. Hsu, and C.-H. Tang, “IL-8 increases integrin expression and cell motility in human chondrosarcoma cells,” Journal of Cellular Biochemistry, vol. 112, no. 9, pp. 2549–2557, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. T.-H. Lai, Y.-C. Fong, W.-M. Fu, R.-S. Yang, and C.-H. Tang, “Stromal cell-derived factor-1 increase αvβ3 integrin expression and invasion in human chondrosarcoma cells,” Journal of Cellular Physiology, vol. 218, no. 2, pp. 334–342, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. C.-H. Hou, R.-S. Yang, S.-M. Hou, and C.-H. Tang, “TNF-α increases αvβ3 integrin expression and migration in human chondrosarcoma cells,” Journal of Cellular Physiology, vol. 226, no. 3, pp. 792–799, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. S.-N. Yang, H.-T. Chen, H.-K. Tsou et al., “Leptin enhances cell migration in human chondrosarcoma cells through OBRl leptin receptor,” Carcinogenesis, vol. 30, no. 4, pp. 566–574, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. Y.-C. Chiu, D.-C. Shieh, K.-M. Tong et al., “Involvement of AdipoR receptor in adiponectin-induced motility and α2β1 integrin upregulation in human chondrosarcoma cells,” Carcinogenesis, vol. 30, no. 10, pp. 1651–1659, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. C.-Y. Lee, M.-J. Su, C.-Y. Huang et al., “Macrophage migration inhibitory factor increases cell motility and up-regulates αvβ3 integrin in human chondrosarcoma cells,” Journal of Cellular Biochemistry, vol. 113, no. 5, pp. 1590–1598, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. Y.-Y. Yeh, C.-C. Chiao, W.-Y. Kuo et al., “TGF-β1 increases motility and αvβ3 integrin up-regulation via PI3K, Akt and NF-κB-dependent pathway in human chondrosarcoma cells,” Biochemical Pharmacology, vol. 75, no. 6, pp. 1292–1301, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. Y.-C. Fong, T.-M. Li, C.-M. Wu et al., “BMP-2 increases migration of human chondrosarcoma cells via PI3K/Akt pathway,” Journal of Cellular Physiology, vol. 217, no. 3, pp. 846–855, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. C.-M. Su, D.-Y. Lu, C.-J. Hsu et al., “Glial cell-derived neurotrophic factor increases migration of human chondrosarcoma cells via ERK and NF-κB pathways,” Journal of Cellular Physiology, vol. 220, no. 2, pp. 499–507, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. C.-J. Hsu, T.-Y. Lin, C.-C. Kuo et al., “Involvement of integrin up-regulation in RANKL/RANK pathway of chondrosarcomas migration,” Journal of Cellular Biochemistry, vol. 111, no. 1, pp. 138–147, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. J.-F. Liu, Y.-C. Fong, C.-S. Chang et al., “Cyclooxygenase-2 enhances α2β1 integrin expression and cell migration via EP1 dependent signaling pathway in human chondrosarcoma cells,” Molecular Cancer, vol. 9, article 43, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. W.-H. Yang, J.-T. Chang, S.-F. Hsu et al., “Bradykinin enhances cell migration in human chondrosarcoma cells through BK receptor signaling pathways,” Journal of Cellular Biochemistry, vol. 109, no. 1, pp. 82–92, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. C.-H. Tang, Y.-T. Keng, and J.-F. Liu, “HMGB-1 induces cell motility and α5β1 integrin expression in human chondrosarcoma cells,” Cancer Letters, vol. 322, no. 1, pp. 98–106, 2012. View at Publisher · View at Google Scholar · View at Scopus
  60. J.-B. Vincourt, S. Etienne, J. Cottet et al., “C-propeptides of procollagens Iα1 and II that differentially accumulate in enchondromas versus chondrosarcomas regulate tumor cell survival and migration,” Cancer Research, vol. 70, no. 11, pp. 4739–4748, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. Z. Wang, J. Bryan, C. Franz, N. Havlioglu, and L. J. Sandell, “Type IIB procollagen NH2-propeptide induces death of tumor cells via interaction with integrins αvβ3 and αvβ5,” The Journal of Biological Chemistry, vol. 285, no. 27, pp. 20806–20817, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. Y.-J. Chen, Y.-Y. Wei, H.-T. Chen et al., “Osteopontin increases migration and MMP-9 up-regulation via αvβ3 integrin, FAK, ERK, and NF-κB-dependent pathway in human chondrosarcoma cells,” Journal of Cellular Physiology, vol. 221, no. 1, pp. 98–108, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. S. C. Hsu, J. H. Lin, S. W. Weng et al., “Crude extract of Rheum palmatum inhibits migration and invasion of U-2 OS human osteosarcoma cells by suppression of matrix metalloproteinase-2 and -9,” BioMedicine, vol. 3, no. 3, pp. 120–129, 2013. View at Google Scholar
  64. T.-W. Tan, W.-H. Yang, Y.-T. Lin et al., “Cyr61 increases migration and MMP-13 expression via αvβ3 integrin, FAK, ERK and AP-1-dependent pathway in human chondrosarcoma cells,” Carcinogenesis, vol. 30, no. 2, pp. 258–268, 2009. View at Publisher · View at Google Scholar · View at Scopus
  65. T.-W. Tan, C.-H. Lai, C.-Y. Huang et al., “CTGF enhances migration and MMP-13 up-regulation via αvβ3 integrin, FAK, ERK, and NF-κB-dependent pathway in human chondrosarcoma cells,” Journal of Cellular Biochemistry, vol. 107, no. 2, pp. 345–356, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. H.-E. Tzeng, J.-C. Chen, C.-H. Tsai et al., “CCN3 increases cell motility and MMP-13 expression in human chondrosarcoma through integrin-dependent pathway,” Journal of Cellular Physiology, vol. 226, no. 12, pp. 3181–3189, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. H.-P. Kim, M.-S. Lee, J. Yu et al., “TGF-β1 (transforming growth factor-β1)-mediated adhesion of gastric carcinoma cells involves a decrease in Ras/ERKs (extracellular-signal- regulated kinases) cascade activity dependent on c-Src activity,” Biochemical Journal, vol. 379, no. 1, pp. 141–150, 2004. View at Publisher · View at Google Scholar · View at Scopus
  68. T. Narita, N. Kawakami-Kimura, M. Sato et al., “Alteration of integrins by heparin-binding EGF-like growth factor in human breast cancer cells,” Oncology, vol. 53, no. 5, pp. 374–381, 1996. View at Google Scholar · View at Scopus
  69. B. Xue, W. Wu, K. Huang et al., “Stromal cell-derived factor-1 (SDF-1) enhances cells invasion by alphavbeta6 integrin-mediated signaling in ovarian cancer,” Molecular and Cellular Biochemistry, vol. 380, no. 1-2, pp. 177–184, 2013. View at Publisher · View at Google Scholar
  70. S.-W. Wang, H.-H. Wu, S.-C. Liu et al., “CCL5 and CCR5 interaction promotes cell motility in human osteosarcoma,” PLoS ONE, vol. 7, no. 4, Article ID e35101, 2012. View at Publisher · View at Google Scholar · View at Scopus
  71. H. Sawai, H. Funahashi, M. Yamamoto et al., “Interleukin-1 α enhances integrin α6β 1 expression and metastatic capability of human pancreatic cancer,” Oncology, vol. 65, no. 2, pp. 167–173, 2003. View at Publisher · View at Google Scholar · View at Scopus
  72. H. Sawai, Y. Okada, H. Funahashi et al., “Interleukin-1α enhances the aggressive behavior of pancreatic cancer cells by regulating the α6β1-integrin and urokinase plasminogen activator receptor expression,” BMC Cell Biology, vol. 7, article 8, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. C.-H. Hou, Y.-C. Chiang, Y.-C. Fong, and C.-H. Tang, “WISP-1 increases MMP-2 expression and cell motility in human chondrosarcoma cells,” Biochemical Pharmacology, vol. 81, no. 11, pp. 1286–1295, 2011. View at Publisher · View at Google Scholar · View at Scopus
  74. Y.-C. Fong, C.-Y. Lin, Y.-C. Su et al., “CCN6 enhances ICAM-1 expression and cell motility in human chondrosarcoma cells,” Journal of Cellular Physiology, vol. 227, no. 1, pp. 223–232, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. C. Mas-Moruno, F. Rechenmacher, and H. Kessler, “Cilengitide: the first anti-angiogenic small molecule drug candidate. Design, synthesis andclinical evaluation,” Anti-Cancer Agents in Medicinal Chemistry, vol. 10, no. 10, pp. 753–768, 2010. View at Google Scholar · View at Scopus
  76. J. S. Desgrosellier and D. A. Cheresh, “Integrins in cancer: biological implications and therapeutic opportunities,” Nature Reviews Cancer, vol. 10, no. 1, pp. 9–22, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. C. Mas-Moruno, J. G. Beck, L. Doedens et al., “Increasing αvβ3 selectivity of the anti-angiogenic drug cilengitide by N-methylation,” Angewandte Chemie, vol. 50, no. 40, pp. 9496–9500, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. M. E. Cianfrocca, K. A. Kimmel, J. Gallo et al., “Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours,” British Journal of Cancer, vol. 94, no. 11, pp. 1621–1626, 2006. View at Publisher · View at Google Scholar · View at Scopus
  79. O. Stoeltzing, W. Liu, N. Reinmuth et al., “Inhibition of integrin α5β1 function with a small peptide (ATN-161) plus continuous 5-fu infusion reduces colorectal liver metastases and improves survival in mice,” International Journal of Cancer, vol. 104, no. 4, pp. 496–503, 2003. View at Publisher · View at Google Scholar · View at Scopus
  80. P. Khalili, A. Arakelian, G. Chen et al., “A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo,” Molecular Cancer Therapeutics, vol. 5, no. 9, pp. 2271–2280, 2006. View at Publisher · View at Google Scholar · View at Scopus
  81. J. C. Gutheil, T. N. Campbell, P. R. Pierce et al., “Targeted antiangiogenic therapy for cancer using vitaxin: a humanized monoclonal antibody to the integrin α(v)β3,” Clinical Cancer Research, vol. 6, no. 8, pp. 3056–3061, 2000. View at Google Scholar · View at Scopus
  82. A. Gramoun, S. Shorey, J. D. Bashutski et al., “Effects of Vitaxin, a novel therapeutic in trial for metastatic bone tumors, on osteoclast functions in vitro,” Journal of Cellular Biochemistry, vol. 102, no. 2, pp. 341–352, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. V. Ramakrishnan, V. Bhaskar, D. A. Law et al., “Preclinical evaluation of an anti-α5β1 integrin antibody as a novel anti-angiogenic agent,” Journal of Experimental Therapeutics and Oncology, vol. 5, no. 4, pp. 273–286, 2006. View at Google Scholar · View at Scopus
  84. V. Bhaskar, D. Zhang, M. Fox et al., “A function blocking anti-mouse integrin α5β1 antibody inhibits angiogenesis and impedes tumor growth in vivo,” Journal of Translational Medicine, vol. 5, article 61, 2007. View at Publisher · View at Google Scholar · View at Scopus
  85. A. D. Ricart, A. W. Tolcher, G. Liu et al., “Volociximab, a chimeric monoclonal antibody that specifically binds α5β1 integrin: a phase l, pharmacokinetic, and biological correlative study,” Clinical Cancer Research, vol. 14, no. 23, pp. 7924–7929, 2008. View at Publisher · View at Google Scholar · View at Scopus
  86. J. H. Hutchinson, W. Halczenko, K. M. Brashear et al., “Nonpeptide αvβ3 antagonists. 8. In vitro and in vivo evaluation of a potent αvβ3 antagonist for the prevention and treatment of osteoporosis,” Journal of Medicinal Chemistry, vol. 46, no. 22, pp. 4790–4798, 2003. View at Publisher · View at Google Scholar · View at Scopus
  87. M. G. Murphy, K. Cerchio, S. A. Stoch, K. Gottesdiener, M. Wu, and R. Recker, “Effect of L-000845704, an αVβ3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 4, pp. 2022–2028, 2005. View at Publisher · View at Google Scholar · View at Scopus
  88. A. M. Badger, S. Blake, R. Kapadia et al., “Disease-modifying activity of SB, 273005, an orally active, nonpeptide alphavbeta3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis,” Arthritis & Rheumatism, vol. 44, no. 1, pp. 128–137, 2001. View at Google Scholar
  89. F. Lamoureux, P. Richard, Y. Wittrant et al., “Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption,” Cancer Research, vol. 67, no. 15, pp. 7308–7318, 2007. View at Publisher · View at Google Scholar · View at Scopus
  90. F. Lamoureux, G. Picarda, J. Rousseau et al., “Therapeutic efficacy of soluble receptor activator of nuclear factor-κB-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma,” Molecular Cancer Therapeutics, vol. 7, no. 10, pp. 3389–3398, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. J. Rousseau, V. Escriou, F. Lamoureux et al., “Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models,” Journal of Bone and Mineral Research, vol. 26, no. 10, pp. 2452–2462, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. D. H. Henry, L. Costa, F. Goldwasser et al., “Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma,” Journal of Clinical Oncology, vol. 29, no. 9, pp. 1125–1132, 2011. View at Publisher · View at Google Scholar · View at Scopus
  93. K. Fizazi, M. Carducci, M. Smith et al., “Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study,” The Lancet, vol. 377, no. 9768, pp. 813–822, 2011. View at Publisher · View at Google Scholar · View at Scopus
  94. M. R. Smith, F. Saad, R. Coleman et al., “Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial,” The Lancet, vol. 379, no. 9810, pp. 39–46, 2012. View at Publisher · View at Google Scholar · View at Scopus
  95. M.-C. Maa and T.-H. Leu, “Activation of Toll-like receptors induces macrophage migration via the iNOS/Src/FAK pathway,” BioMedicine, vol. 1, no. 1, pp. 11–15, 2011. View at Publisher · View at Google Scholar · View at Scopus
  96. J. W. Lee, Y. H. Kim, H. B. Park et al., “The C-terminal domain of focal adhesion kinase reduces the tumor cell invasiveness in chondrosarcoma cell lines,” Journal of Orthopaedic Research, vol. 21, no. 6, pp. 1071–1080, 2003. View at Publisher · View at Google Scholar · View at Scopus
  97. J. R. Infante, D. R. Camidge, L. R. Mileshkin et al., “Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors,” Journal of Clinical Oncology, vol. 30, no. 13, pp. 1527–1533, 2012. View at Publisher · View at Google Scholar
  98. D. R. Clemmons and L. A. Maile, “Minireview: integral membrane proteins that function coordinately with the insulin-like growth factor I receptor to regulate intracellular signaling,” Endocrinology, vol. 144, no. 5, pp. 1664–1670, 2003. View at Publisher · View at Google Scholar · View at Scopus
  99. L. A. Maile and D. R. Clemmons, “The αVβ3 integrin regulates insulin-like growth factor I (IGF-I) receptor phosphorylation by altering the rate of recruitment of the Src-homology 2-containing phosphotyrosine phosphatase-2 to the activated IGF-I receptor,” Endocrinology, vol. 143, no. 11, pp. 4259–4264, 2002. View at Publisher · View at Google Scholar · View at Scopus
  100. J. A. Toretsky and R. Gorlick, “IGF-1R targeted treatment of sarcoma,” The Lancet Oncology, vol. 11, no. 2, pp. 105–106, 2010. View at Publisher · View at Google Scholar · View at Scopus
  101. E. D. Fleuren, Y. M. Versleijen-Jonkers, S. Heskamp et al., “The strength of small: improved targeting of Insulin-like Growth Factor-1 Receptor (IGF-1R) with F(ab')(2)-R1507 fragments in Ewing sarcomas,” Journal of Cancer, vol. 49, no. 13, pp. 2851–2858, 2013. View at Google Scholar
  102. I. Asmane, E. Watkin, L. Alberti et al., “Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas,” European Journal of Cancer, vol. 48, no. 16, pp. 3027–3035, 2012. View at Publisher · View at Google Scholar
  103. W. D. Tap, G. Demetri, P. Barnette et al., “Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors,” Journal of Clinical Oncology, vol. 30, no. 15, pp. 1849–1856, 2012. View at Publisher · View at Google Scholar
  104. A. S. Pappo, S. R. Patel, J. Crowley et al., “R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: Results of a phase II Sarcoma Alliance for research through Collaboration study,” Journal of Clinical Oncology, vol. 29, no. 34, pp. 4541–4547, 2011. View at Publisher · View at Google Scholar · View at Scopus
  105. H. Juergens, N. C. Daw, B. Geoerger et al., “Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma,” Journal of Clinical Oncology, vol. 29, no. 34, pp. 4534–4540, 2011. View at Publisher · View at Google Scholar · View at Scopus
  106. C. M. Wu, T. M. Li, T. W. Tan, Y. C. Fong, and C. H. Tang, “Berberine reduces the metastasis of chondrosarcoma by modulating the αvβ3 integrin and the PKCδ, c-Src, and AP-1 signaling pathways,” Evidence-based Complementary and Alternative Medicine, vol. 2013, Article ID 423164, 10 pages, 2013. View at Publisher · View at Google Scholar